Endomorphin-1 vs Somatostatin
Head-to-head comparison of Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Endomorphin-1 | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Tyr-Pro-Trp-Phe-NH2 | Somatostatin-14 |
| Molecular Weight | 610.71 Da | 1637.85 |
| Half-Life | Minutes in plasma | 1-3 min |
| Amino Acids | 4 | 14 |
| Typical Dose | 0.1-10 ug per animal | N/A|N/A |
| Route | Intrathecal / subcutaneous | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 600 | 84 |
| Research Status | Pre-clinical | Approved |
Endomorphin-1 Benefits
- ✓mu-opioid selectivity
- ✓potent antinociception
- ✓endogenous peptide scaffold
- ✓useful for receptor-discovery studies
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
Endomorphin-1 Dosing
Intrathecal 0.1-10 ug per animal|Subcutaneous 0.1-5 ug per animal|In vitro 0.1-100 nM
Somatostatin Dosing
N/A|N/A
Endomorphin-1 Side Effects
- ⚠respiratory depression at high exposure
- ⚠sedation
- ⚠tolerance and dependence potential
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
Endomorphin-1
Endomorphin-1 is a key research peptide in studies of endogenous mu-opioid signaling and spinal analgesia. Like other peptide analgesics, its main translational hurdles are enzymatic instability, limited oral bioavailability, and delivery across barriers.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.